Conavi Medical Corp. Announces Filing of Amended & Restated Final Prospectus

Core Viewpoint - Conavi Medical Corp. is conducting a public offering of common shares and pre-funded common share purchase warrants to raise between $12 million and $15 million for regulatory clearance and market release of its Novasight Hybrid system, along with working capital needs [2][3][6]. Group 1: Offering Details - The offering consists of a minimum of 26,666,667 and a maximum of 33,333,333 securities priced at $0.45 per common share or $0.44999 per pre-funded warrant [2]. - Each pre-funded warrant allows the holder to acquire one common share at an exercise price of $0.00001, with no expiration and can be exercised on a cashless basis [2]. - The offering may be completed in one or more tranches, with an expected initial closing date around January 13, 2026, subject to regulatory approvals [6]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to obtain US FDA 510(k) clearance for the Novasight Hybrid system and to facilitate a targeted market release in the United States [3]. - Additional proceeds will be allocated for working capital and general corporate purposes [3]. Group 3: Agent and Fees - The company will pay the agent, Bloom Burton Securities Inc., a cash fee of 6.5% of the gross proceeds and grant compensation options equal to 6.5% of the total number of securities issued [7]. - A reduced cash commission of 3.25% will apply for certain purchasers on a president's list, with no compensation options for those sales [7]. Group 4: Regulatory Filings - An amended and restated final short form prospectus was filed on January 7, 2026, with securities regulatory authorities in Alberta, British Columbia, and Ontario [5]. - The offering is subject to customary closing conditions, including necessary regulatory and stock exchange approvals [6]. Group 5: Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures [12]. - The Novasight Hybrid system combines intravascular ultrasound and optical coherence tomography into a single device, enabling simultaneous imaging of coronary arteries [12].